Psychogenics Pharmaceuticals
L-Dopa-Induced Dyskinesia
On May 22, 2013, the Company (AMBS) entered into a letter of intent to in-license a Phase II drug candidate in L-Dopa-Induced Dyskinesia Parkinson's Disease from an undisclosed 3rd party. Once licensed, the Company intends to initiate a Phase IIb clinical trial within 12 months...
the Agreement is an "LOI" to in-license Ph. II drug candidate L-Dopa-Induced Dyskinesia PD from an undisclosed 3rd party - one of several suggested Pharma's.
1.) Endo Pharmaceuticals (Amantadine)
2.) Adamas Pharmaceuticals (Nurlin)
3.) Novartis Pharmaceuticals (Mavoglurant)
4.) Addex Therapeutics (Dipraglurant)
5.) Psychogenics Pharmaceuticals (Eltoprazine)
6.) Avanir Pharmaceuticals (Nuedexta)
7.) Neurim Pharmaceuticals (Neu-120)
******************************************************************************************
Dr. Lowe is President & CEO of NeuroAssets, Sarl, a Swiss-based neuroscience-focused consulting firm, providing advisory services to pharmaceutical, venture capital and biotechnology companies throughout the world. Dr. Lowe previously served as the Chief Scientific Officer of Psychogenics, Inc. and before that as Director and Chief Scientific Officer of Memory Pharmaceuticals, Inc., a biotechnology company pursuing innovative treatments for Alzheimer's and Schizophrenia. Prior to Memory Pharmaceuticals, Dr. Lowe served as the Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group, Fidelity Investments in Boston, MA, an investment firm focused on the healthcare industry. He also served as President, CEO and Director of Envivo Pharmaceuticals, a Fidelity-funded pharmaceutical company pursuing new treatments for Alzheimer's disease now in Phase 3 development. Dr. Lowe also served as Vice-President and Therapeutic Area Head, Central Nervous System, at Roche Pharmaceuticals, Vice President & Global Therapeutic Area Head of Central Nervous System Research at Bayer AG., and Head of CNS Biology and Deputy Head of CNS Research at Sandoz Ltd (now Novartis). Dr. Lowe received his PhD in neurobiology from the University of Leeds, UK.
